Diabetes Prevention Program
The Diabetes Prevention Program (DPP) was a major clinical trial, or research study, aimed at discovering whether either diet and exercise or the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in people with impaired glucose tolerance (IGT).
The answer is yes. In fact, the DPP found that over the three years of the study, diet and exercise sharply reduced the chances that a person with IGT would develop diabetes. Metformin also reduced risk, although less dramatically. The DPP resolved these questions so quickly that, on the advice of an external monitoring board, the program was halted a year early. The researchers published their findings in the February 7, 2002, issue of the New England Journal of Medicine.
If you have diabetes, it's important to avoid getting the flu. Flu, or influenza, is a viral infection of the respiratory system and muscles. While everyone has a chance of catching flu, having diabetes makes it harder to fight off viruses that cause flu. Flu and other viral infections can create added stress in your body, which can affect your blood sugar levels and increase the chance of serious health complications.
Read the Diabetes and the Flu article > >
DPP Study Design and Goals
In the DPP, participants from 27 clinical centers around the country were randomly split into different treatment groups. The first group, called the lifestyle intervention group, received intensive training in diet, exercise, and behavior modification. By eating less fat and fewer calories and exercising for a total of 150 minutes a week, they aimed to lose 7% of their body weight and maintain that loss.
The second group took 850 mg of metformin twice a day. The third group received placebo pills instead of metformin. The metformin and placebo groups also received information on diet and exercise, but no intensive counseling efforts. A fourth group was treated with the drug troglitazone (Rezulin), but this part of the study was discontinued after researchers discovered that troglitazone can cause serious liver damage.
All 3,234 study participants were overweight and had IGT, which are well recognized risk factors for the development of type 2 diabetes. In addition, 45% of the participants were from minority groups -- African American, Hispanic American/Latino, Asian American or Pacific Islander, or American Indian -- that are at increased risk of developing diabetes.
Type 2 Diabetes and Prediabetes
Diabetes is a disorder that affects the way your body uses digested food for growth and energy. Normally, the food you eat is broken down into sugar (glucose). The glucose then passes into your bloodstream, where it is used by your cells for growth and energy. For glucose to reach your cells, however, insulin must be present. Insulin is a hormone produced by your pancreas, a hand-sized gland behind your stomach.
Most people with type 2 diabetes have two problems: the pancreas may not produce enough insulin, and fat, muscle, and liver cells cannot use it effectively. This means that sugar builds up in the blood, overflows into the urine, and passes out of the body -- without fulfilling its role as the body's main source of fuel.
About 23.6 million people in the U.S. have diabetes. Ninety percent to 95% of people with diabetes have type 2 diabetes. Diabetes is the main cause of kidney failure, limb amputation, and new-onset blindness in American adults. People with diabetes are also two to four times more likely than people without diabetes to develop heart disease.
WebMD Medical Reference

